Jennifer P. Lee, PharmD, BCPS - Paralyzed Veterans of America

More documents

Recommendations

Info

Methodology • Volume <strong>of</strong> distribution calculations 17 : o Vancomycin • V d = 0.17(age) + 0.22 (TBW) + 15 o Aminoglycosides • Peak levels were used to calculate V d 17 Rushing TA. J Pharm Technol, 2001; 17: 33-8.
Methodology • Actual drug clearance (CL DRUG ) • CG CrCl (CL CG ) • Modified CG CrCl (CL M ) • Adjusted 24-hour endogenous CrCl (CL 24H ) • MDRD equation • CKD-EPI equation
Page 1 and 2: Evaluation of Methods to Estimate R
Page 3 and 4: Disclosures • Jennifer Lee, Pharm
Page 5 and 6: VA Long Beach Healthcare System •
Page 7 and 8: Creatinine • A muscle breakdown p
Page 9 and 10: Vancomycin & Aminoglycosides • Do
Page 11 and 12: Cockcroft-Gault (CG) 7 CL CG (mL/mi
Page 13 and 14: MDRD equation 8 4-Variable MDRD: eG
Page 15 and 16: CKD-EPI equation 9 eGFR = 141 x min
Page 17 and 18: 24-Hour Endogenous Creatinine Clear
Page 19 and 20: Inclusion Criteria • Patients at
Page 21: Methodology • VA electronic medic
Page 25 and 26: Results
Page 27 and 28: Evaluation of different methods to
Page 29 and 30: Number of Patients Difference betwe
Page 31 and 32: Actual Drug Clearance (mL/min) 120
Page 33 and 34: CL DRUG vs. CL SCI • T-Test showe
Page 35 and 36: DISCUSSION
Page 37 and 38: Discussion • CL SCI = 2.3286 * x
Page 39 and 40: Conclusion • Current methods used
Page 41 and 42: References 1. Macdiarmid S, Mcintyr
Page 43: Post-Test Assessment Questions •

Jennifer P. Lee, PharmD, BCPS - Paralyzed Veterans of America

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?